Guggenheim raised the firm’s price target on AbbVie (ABBV) to $227 from $216 and keeps a Buy rating on the shares following what the firm calls “another strong quarter.” Management raised full-year revenue and EPS guidance for the second time this year, adds the analyst, who update the firm’s model to reflect higher Skyrizi and neuroscience estimates, a steeper Humira erosion curve, and slightly lower aesthetics estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $207 from $205 at Evercore ISI
- AbbVie price target raised to $236 from $227 at Raymond James
- AbbVie Receives Buy Rating from Terence Flynn Due to Strong Financial Performance and Growth Potential
- AbbVie: Balancing Strong Performance with Pricing Uncertainties and Valuation Concerns
- AbbVie Reports Strong Q2 2025 Financial Results